Table 1.
Participant Characteristics (n=107)
| Characteristic | Mean (SD) | Range | N (%) |
|---|---|---|---|
| Age |
63.9 (9.0) |
45.0–84.0 |
|
| Married |
71 (66.4) |
||
| Education | |||
| Some high school | 6 (5.6) | ||
| Finished high school | 18 (16.8) | ||
| Vocational Training / Some college | 22 (20.6) | ||
| College degree | 33 (30.8) | ||
| Graduate degree | 25 (23.3) | ||
| Missing |
3 (2.8) |
||
| Race | |||
| White | 87 (81.3) | ||
| African American | 17 (15.9) | ||
| Other | 2 (1.8) | ||
| Missing |
1 (1) |
||
| Ethnicity | |||
| Hispanic | 2 (1.9) | ||
| Non Hispanic | 83 (77.6) | ||
| Missing |
22 (20.5) |
||
| Stage | |||
| Stage I | 42 (39.3) | ||
| Stage II | 53 (49.5) | ||
| Stage III |
12 (11.2) |
||
| Surgery Type | |||
| Lumpectomy | 58 (54.2) | ||
| Mastectomy |
49 (45.8) |
||
| Time from Surgery (Months) |
41.19 (30.1) |
2.8–134.4 |
|
| Chemotherapy (% yes) |
56 (52.3) |
||
| Radiation (% yes) |
81 (75.7) |
||
| Type of Endocrine Therapy | |||
| Tamoxifen | 17 (15.9) | ||
| AI |
90 (84.1) |
||
| Months on current endocrine therapy (Months) |
25.1 (21.9) |
0.00–97.8 |
|
| Months on any endocrine therapy (Months) |
37.4 (30.3) |
1.15–130.3 |
|
| ACE Comorbidity index | |||
| 0 | 36 (33.6) | ||
| 1 | 50 (46.7) | ||
| 2 | 15 (14.0) | ||
| 3 |
6 (5.6) |
||
| Grip strength (mmHg) | |||
| Dominant hand | 47.7 (14.4) | 10.0–80.0 | |
| Non-dominant hand |
45.7 (12.0) |
12.0–75.0 |
|
| Timed Up and Go (seconds) | 10.3 (3.3) | 6.0–30.0 |
Note: the ACE Comorbidity Index is a tool used to predict survival among various types of patients with cancer based on co-morbidity score.i